Home >> News >> Business >> Companion Diagnostics Market to Reach Worth USD 14,453.3 Mn by 2023

Companion Diagnostics Market to Reach Worth USD 14,453.3 Mn by 2023

The purpose of the report is to illustrate the state of the market of Companion Diagnostics, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.

Browse here for full report: https://www.credenceresearch.com/report/companion-diagnostics-market

Market Insights

Companion diagnostic tests are used to identify suitable patients for administering specific drugs and monitoring the prognosis of drug effects on the disease. This concept of combining a drug with a diagnostic test is known as predictive medicine or personalized medicine. A companion diagnostic test has the ability to predict the risks of the disease and monitor its therapeutic response. On the basis of technology the companion diagnostics market has been segmented into polymerase chain reaction, immunohistochemistry, In-situ hybridization test, gene sequencing and others. The others segment includes tests such as monoclonal antibodies test and cellular immune testing. The polymerase chain reaction technique is the largest segment in the global companion diagnostics market. On the basis of indication the global companion diagnostics market has been segmented as oncology, cardiovascular diseases, virology and autoimmune diseases. The oncology segment has been further segmented on the basis of various cancers such as breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma and other cancer.  The oncology segment held the largest market in the global companion diagnostics by indication and is expected to be the highest grossing segment through the forecast period. The major factors driving the oncology segment include development of majority of companion diagnostics for detection of various cancer biomarkers.

The geographical segmentation of the global companion diagnostics market comprises North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. In base year 2015, North America accounted for the largest market in the global companion diagnostics. In North America, the US represented the largest market for companion diagnostic tests. Asia Pacific is expected to grow at a highest rate during the forecast period due increased adoption, technological advancements, and demand for personalized medicine. the increase in the prevalence of cancer and associated disorders, the increase in healthcare expenditure, and the increase in the level of awareness among the population. Thus, the APAC region is expected to adopt companion diagnostics tests at a rapid rate during the forecast period.

The key players operating in the global companion diagnostics market include Abbott Laboratories Inc., Agilent Technologies Inc., bioMerieux SA, Qiagen N.V., Roche Holdings AG, Thermo Fisher Scientific Inc. The other notable players include Ventana Medical Systems, Myriad Genetics, Leica Microsystems and others.

Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Companion Diagnostics Market Portaiture
2.2 Global Companion Diagnostics Market, by Indication, 2015 (USD Mn)
2.3 Global Companion Diagnostics Market, by Technology, 2015 (USD Mn)
2.4 Companion Diagnostics Market Share, by Geography, 2015 (Value %)

Chapter 3 Companion Diagnostics : Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.2 Epidemiology of Thyroid Disorders
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Increased Focus on Cost Cutting in Drug Discovery and Development
3.3.1.2 Increased Popularity of Personalized Medicines
3.3.1.3 Rapid Advancements in Science and Technology
3.3.1.4 Increase in Prevalence of Cancer and Other Disorders
3.3.2 Challenges
3.3.2.1 High Cost Involved in Companion Diagnostics Development
3.3.1.2 Stringent Regulations
3.3.1.3 Need for Multidisciplinary Approach to Develop Efficient Companion Diagnostics
3.3.3 Opportunities
3.3.3.1 Increase in Number of Product Launches and Approvals
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis By Key Players, 2015 (Value %)
3.6 Vendor Landscape

Chapter 4 Companion Diagnostics Market, by Indications
4.1 Preface
4.2 Oncology
4.2.1. Breast Cancer
4.2.2. Colorectal Cancer
4.2.1. Gastric Cancer
4.2.2. Lung Cancer
4.2.1. Melanoma
4.2.2. Others
4.3 Cardiovascular Diseases
4.4 Infectious Diseases
4.5 Autoimmune Diseases

Chapter 5 Companion Diagnostics Market, by Technology
5.1 Overview
5.2 Polymerase Chain Reaction
5.3 Immunohistochemistry (IHC)
5.4 In-Situ Hybridization Test (ISH)
5.5 Gene Sequencing
5.6 Others

Chapter 6 Companion Diagnostics Market, By Geography
6.1 Overview
6.2 North America
6.2.1. U.S.
6.2.2. Canada
6.3 Europe
6.3.1. U.K.
6.3.2. Germany
6.3.3. Rest of Europe
6.4 Asia Pacific
6.4.1. Japan
6.4.2. China
6.4.3. Rest of Asia Pacific
6.4 Latin America
6.5 Middle East and Africa

Chapter 7 Company Profiles
7.1 Abbott Laboratories Inc.
7.1.1 Business Description
7.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
7.1.4 News Coverage
7.2 Agilent Technologies, Inc.
7.2.1 Business Description
7.2.2 Financial Health and Budget Allocation
7.2.3 Product Portfolio
7.2.4 News Coverage
7.3 bioMerieux SA
7.3.1 Business Description
7.3.2 Financial Health and Budget Allocation
7.3.3 Product Portfolio
7.3.4 News Coverage
7.4 Qiagen N.V.
7.4.1 Business Description
7.4.2 Financial Health and Budget Allocation
7.4.3 Product Portfolio
7.4.4 News Coverage
7.5 Roche Holdings AG
7.5.1 Business Description
7.5.2 Financial Health and Budget Allocation
7.5.3 Product Portfolio
7.5.4 News Coverage
7.6 Thermo Fisher Scientific
7.6.1 Business Description
7.6.2 Financial Health and Budget Allocation
7.6.3 Product portfolio
7.6.4 News Coverage
7.7 Ventana Medical Systems
7.7.1 Business Description
7.7.2 Financial Health and Budget Allocation
7.7.3 Product Portfolio
7.7.4 News Coverage
7.8 Myriad Genetics
7.8.1 Business Description
7.8.2 Financial Health and Budget Allocation
7.8.3 Product Portfolio
7.8.4 News Coverage
7.9 Leica Microsystems
7.9.1 Business Description
7.9.2 Financial Health and Budget Allocation
7.9.3 Product Portfolio
7.9.4 News Coverage
7.10 Other Notable Players

Why was the report written?

This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Companion Diagnostics buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.

What is the current market landscape and what is changing?

Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.

The report on the market of Companion Diagnostics contains:

Analysis and forecast of Companion Diagnostics market dynamics;

Analysis of domestic production, market shares of the main market players;

Analysis of exports and imports;

Analysis of factors, leading the development of the Companion Diagnostics market;

Assessment and forecast of Companion Diagnostics market development;

Financial and business profiles of the leading companies in the Companion Diagnostics industry.

Scope

– Up to date working Companion Diagnostics data by major regions in the world, the forecast of planned capacity additions by 2026

– The annual breakdown of capital expenditure spending on proposed Companion Diagnostics for the period 2018 to 2026

– Planned Companion Diagnostics additions and capital expenditure spending by key countries and companies across the world

– Planned capital expenditure spending on new Companion Diagnostics projects by region, key countries, and companies

– Details of major planned Companion Diagnostics projects in the world up to 2026

Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/58078

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Contact Us:

Credence Research Inc.

105 N 1st ST #429

SAN JOSE

CA 95103

United States

Toll Free (US/CANADA): +1-800-361-8290

Web: https://www.credenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *